Special pharmacokinetics of fluconazole in septic, obese and burn patients.
Although there are many potential changes of pharmacokinetic parameters in patients with thermal injury, obesity or septicemia, data about the actual effect on pharmacokinetics and clinical efficacy of fluconazole are very limited. As current dosing recommendations are derived from healthy subjects and patients with normal weight, these recommendations may be inaccurate when applied to the patient populations mentioned above. Pharmacokinetic data of 14 patients with thermal injury were reviewed and revealed a shorter half life and more rapid clearance of fluconazole. In a subgroup of five patients, distribution volume was up to 2 times larger as usual with no relationship to creatinine clearance and degree of burns. In one extremely obese patient treated with fluconazole 1200 mg/day, the corresponding mean steady-state plasma concentration and AUC were decreased with an increase of fluconazole clearance possibly due to a larger volume of distribution. In patients with septicemia, fluconazole plasma levels appear to be highly variable. As a considerable number of these patients develops acute renal failure, renal replacement therapy may be indicated which may require substantial dosage modifications of fluconazole.
Pittrow
L
L
Pfizer GmbH, Karlsruhe, Germany.
Penk
A
A
D000328:Adult; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D002056:Burns / Q000378:metabolism*; D015725:Fluconazole / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000378:metabolism; D009765:Obesity / Q000378:metabolism*; D018805:Sepsis / Q000378:metabolism*
D000935:Antifungal Agents; D015725:Fluconazole